Personalized Medicine Universe最新文献_第7页

WITHDRAWN: Corrigendum to “DL-/PO-phosphatidylcholine serves as a memory enhancer for normal healthy subjects” [Pers Med Univ 2 (2013) 16–19] 撤回:“DL-/ po -磷脂酰胆碱可作为正常健康受试者的记忆增强剂”的更正[Pers Med Univ 2 (2013) 16-19]

Personalized Medicine Universe Pub Date : 2015-07-18 DOI: 10.1016/J.PMU.2015.07.001

Takaaki Nishimoto, T. Kanno, A. Gotoh, T. Nishizaki

引用次数: 0

Cancer stem cell markers in lung cancer 肺癌中的癌症干细胞标记物

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.03.007

Takeaki Miyata , Takashi Yoshimatsu , Tetsuya So , Tsunehiro Oyama , Hidetaka Uramoto , Toshihiro Osaki , Ryoichi Nakanishi , Fumihiro Tanaka , Hisao Nagaya , Akinobu Gotoh

{"title":"Cancer stem cell markers in lung cancer","authors":"Takeaki Miyata , Takashi Yoshimatsu , Tetsuya So , Tsunehiro Oyama , Hidetaka Uramoto , Toshihiro Osaki , Ryoichi Nakanishi , Fumihiro Tanaka , Hisao Nagaya , Akinobu Gotoh","doi":"10.1016/j.pmu.2015.03.007","DOIUrl":"10.1016/j.pmu.2015.03.007","url":null,"abstract":"<div><h3>Purpose</h3><p><span>Lung cancer is responsible for most cancer-related deaths. There are two broad types of lung tumors, usually classified as small cell lung cancer<span> (SCLC) and non-small cell lung cancer (NSCLC). Current clinicopathological staging systems provide the advantage of standardized criteria for assessing tumor stage, and a relationship between advancing tumor stage and poor prognosis has been established for NSCLC. However, these staging systems have not led to clear criteria for selection of therapy for individual patients with NSCLC. The concept of therapy based on anatomical location, as used in staging systems, is poorly associated with the cancer stem cell (CSC) characteristics of individual tumor tissues. CSCs may have self-renewal and multipotent differentiation abilities and be responsible for tumor initiation, progression, and metastasis; they are highly resistant to chemoradiotherapy<span>. Therefore, research into CSCs will provide the basis for developing of novel diagnostic and therapeutic strategies. We review aldehyde dehydrogenase isoform 1 (ALDH1), CD133, CD44 and CD166 as CSC markers, as weel as the Wnt/β-catenin pathway, KRAS, and the </span></span></span>embryonic stem cell (ESC) signature.</p></div><div><h3>Study selection</h3><p>PubMed databases were searched for relevant articles.</p></div><div><h3>Results</h3><p>The positivity rate for ALDH1 immunohistochemical (IHC) staining is 19% in patients with stage I NSCLC [1]. The positivity rates for CD133 are 19–48.9% [2–4] and for CD44 are 50.4–67.3% in patients with NSCLC [5,6].</p></div><div><h3>Conclusions</h3><p>CSCs have been identified in lung cancer and will provide new therapeutic targets for lung cancer. Research on these cells could improve the prognosis of lung cancer.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 40-45"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.03.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88107592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

The effects of Hericium erinaceus (Amyloban® 3399) on sleep quality and subjective well-being among female undergraduate students: A pilot study 猴头菌(Amyloban®3399)对女大学生睡眠质量和主观幸福感的影响:一项初步研究

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.03.006

Hisayoshi Okamura Ph.D. , Nobuko Anno Ph.D. , Akira Tsuda Ph.D. , Takahiro Inokuchi Ph.D. , Naohisa Uchimura M.D., Ph.D , Kazutoyo Inanaga M.D., Ph.D.

引用次数: 12

Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs 药物遗传学指导算法估计个体化剂量或抗血栓药物的个体反应

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.04.002

Noritaka Ariyoshi PhD

{"title":"Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs","authors":"Noritaka Ariyoshi PhD","doi":"10.1016/j.pmu.2015.04.002","DOIUrl":"10.1016/j.pmu.2015.04.002","url":null,"abstract":"<div><h3>Purpose</h3><p>Genotyping seems to be regarded as less useful than expected for predicting the inter-individual variation in drug response. We aim to improve the predictive accuracy of genotyping by developing models that also incorporate certain non-genetic factors.</p></div><div><h3>Study selection and results</h3><p><span><span>The anti-coagulant warfarin is widely used to prevent venous thromboembolic events. Although frequent monitoring of the </span>prothrombin time<span><span><span> international normalized ratio (PT-INR) allows an appropriate maintenance dose to be obtained for most individuals, there are some individuals for whom it is difficult to achieve the target PT-INR even when warfarin dose is increased. The anti-platelet drug </span>clopidogrel is typically used with </span>aspirin to prevent cardiovascular events following percutaneous coronary intervention. However, the existence of clopidogrel resistance is a major concern in Asian populations owing to the high prevalence of deficient allele of the </span></span><span><em>CYP2C19</em></span><span><span> gene, which encodes a major enzyme that produces the active metabolite. Individual response to these anti-thrombotic drugs cannot be accurately predicted based on </span>genetic factors<span><span> alone. We have constructed two algorithms, one that predicts the maintenance dose of warfarin and one that estimates individual responses to clopidogrel in outpatients without a device-based platelet function test. We applied </span>Akaike's Information Criterion to evaluate the validity of these algorithms.</span></span></p></div><div><h3>Conclusions</h3><p>In addition to genotyping data, inter-individual variation in non-genetic factors, such as clinical laboratory data, should be considered to predict drug response more accurately in each individual.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 13-22"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.04.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81543620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Molecular genetics of coronary artery disease and ischemic stroke 冠状动脉疾病和缺血性中风的分子遗传学

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.03.002

Yoshiji Yamada

{"title":"Molecular genetics of coronary artery disease and ischemic stroke","authors":"Yoshiji Yamada","doi":"10.1016/j.pmu.2015.03.002","DOIUrl":"10.1016/j.pmu.2015.03.002","url":null,"abstract":"<div><p><span>Coronary artery disease (CAD) and </span>ischemic stroke<span><span><span> are important clinical problems because they are associated with high mortality rates. The main causal and treatable risk factors of CAD and ischemic stroke include hypertension, dyslipidemia, diabetes mellitus, </span>chronic kidney disease, and smoking. In addition, recent studies have highlighted the importance of </span>genetic factors<span> and their interactions with environmental factors<span> in the development of CAD and ischemic stroke. Disease prevention is an important strategy for reducing the overall burden of CAD and ischemic stroke, and identification of markers of disease risk can help in risk prediction and the use of accurate interventions can help decrease the risk of these events. Although genetic linkage analyses and candidate gene association studies have implicated several loci and candidate genes in predisposition to CAD or ischemic stroke, these loci and genes have not been identified definitively. Recent genome-wide association studies (GWASs) have shown that single nucleotide polymorphisms in chromosome 9p21.3 locus and other loci are associated with CAD or ischemic stroke. In this review, I have summarized the genetics of CAD and ischemic stroke and have identified susceptibility genes and loci implicated in these conditions based on the results of GWASs. In addition, I have reviewed GWASs highlighting the association of polymorphisms in the chromosome 9p21.3 locus or other loci with CAD or ischemic stroke. The results of these studies may provide insights into the functions of the implicated genes in the development of CAD and ischemic stroke.</span></span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 4-12"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.03.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78376908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies IV期胃癌患者在接受多肽树突状细胞免疫治疗联合标准治疗后获得完全缓解

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.03.004

Amane Sasada, Megumi Takagi, Shigeki Tabata, Minako Abe, Hiroyuki Abe

引用次数: 4

A novel therapeutic strategy for mycoplasma infectious diseases 支原体传染病的新治疗策略

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.04.005

Kazuhiro Matsuda

{"title":"A novel therapeutic strategy for mycoplasma infectious diseases","authors":"Kazuhiro Matsuda","doi":"10.1016/j.pmu.2015.04.005","DOIUrl":"10.1016/j.pmu.2015.04.005","url":null,"abstract":"<div><p><span>Mycoplasma Infectious Diseases (MID) are </span>systemic illnesses<span> that cause vasculitis and neuritis<span><span>. MID not only includes pneumonia but also diseases such as asthma, arthritis, nephritis<span>, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, and hematologic illnesses. The broader concept of MID encompasses acute to chronic phases with diverse symptoms. Therefore, it is often confusing and difficult to identify Mycoplasma-infected patients among those with incurable diseases, such as autoimmune diseases, </span></span>rheumatic diseases<span>, nervous system disorders<span>, and hematological disorders. Regrettably, conventional diagnosis has only been available for pneumonia, although it is critical to identify MID at early stages for effective medical treatment. A cutting-edge technology has made it possible to measure the amount of specific antibodies to species-specific mycoplasma glycolipid-antigens. This new technology provides a reliable marker to follow the state of MID by monitoring antibody titer fluctuations. A novel therapeutic strategy based on new serological diagnostics is introduced in this review.</span></span></span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 32-39"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.04.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80222930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Safety of a Coleus forskohlii formulation in healthy volunteers 一种黄花菊制剂在健康志愿者中的安全性

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.01.001

Seika Kamohara MD, PhD , Yoshiko Terasaki , Itsuko Horikoshi , Satoshi Sunayama MD, PhD

{"title":"Safety of a Coleus forskohlii formulation in healthy volunteers","authors":"Seika Kamohara MD, PhD , Yoshiko Terasaki , Itsuko Horikoshi , Satoshi Sunayama MD, PhD","doi":"10.1016/j.pmu.2015.01.001","DOIUrl":"10.1016/j.pmu.2015.01.001","url":null,"abstract":"<div><p><em>Coleus forskohlii</em> (CF) is an Indian plant that has been used in Ayurvedic medicine. Several trials have reported the weight-loss effects of CF extract. We investigated the safety and efficacy of CF extract (Forskohlii, DHC Corporation) in healthy volunteers. A dose escalation study was performed to determine the type and frequency of adverse events. Twenty-nine healthy subjects were recruited in an open-label trial and were administered escalating doses from 250 to 1000 mg over a 4-week period. Patients were examined on a daily basis for adverse events. Blood, urine, and stool samples were obtained before and after supplementation in a subset of 10 subjects to assess the safety of the supplement. All 29 subjects completed the study. Intake of CF was associated with minor gastrointestinal adverse events such as soft stool and diarrhea, which appeared to be dose-related. There were no major adverse events. At each dose of CF, either 6 or 7 subjects reported minor GI events. <em>C. forskohlii</em> formulation appears to be well tolerated in daily oral doses up to 1000 mg, and warrants further investigation for its efficacy as a long-term anti-obesity intervention. This study was registered at <span>http://www.umin.ac.jp</span><svg><path></path></svg>, as UMIN000008224.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 63-65"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82933190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Gliomas and genomics 神经胶质瘤和基因组学

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.04.001

Jack Kushner

引用次数: 1

Medical treatment of food allergies should be personalized 食物过敏的药物治疗应该个性化

Personalized Medicine Universe Pub Date : 2015-07-01 DOI: 10.1016/j.pmu.2015.03.005

Naomi Kondo MD, PhD , Manami Kuwabara , Hitomi Kodama , Masumi Kumada , Nobuhiro Hori

引用次数: 2